Study of BRIUMVI for relapsing multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple sclerosis
- You have not yet received your first BRIUMVI treatment dose
- You have not had a live vaccine in the last 4 weeks (or a non-live vaccine in the last 2 weeks)
- You do not have an active infection, like hepatitis B
- You are not currently in another multiple sclerosis drug study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
This study looks at the effects of the MS medication BRIUMVI on pregnancy and baby health. It compares women who took BRIUMVI during pregnancy to those who did not.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.